Abobotulinumtoxina

Summary

Abobotulinumtoxina (CHEMBL2108570) is an approved unknown; indicated across 4 conditions including epicondylitis and severe cutaneous adverse reaction.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 17

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108570
Name	Abobotulinumtoxina
Type	Unknown
Max phase	4

Also known as: Abobotulinumtoxina, RTI-150, RTI150, ABOBOTULINUMTOXINA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
epicondylitis	3	MONDO:0001875	EFO:1001896
severe cutaneous adverse reaction	2	MONDO:0005594	EFO:0006346
plantar fasciitis	2	MONDO:0004833	EFO:1001909

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE4	8
PHASE2	3
Not specified	3
PHASE3	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03935295	PHASE4	RECRUITING	Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis
NCT01732809	PHASE4	COMPLETED	Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses
NCT03639766	PHASE4	TERMINATED	The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud’s Phenomenon
NCT03687736	PHASE4	COMPLETED	Subject Satisfaction With AbobutulinumtoxinA Treatment
NCT03928496	PHASE4	COMPLETED	Abobotulinumtoxina Efficacy in Post-Traumatic Headache
NCT04470401	PHASE4	COMPLETED	The Treatment of Shoulder Pain in Hemiplegic Spastic Patients With Botulinum Toxin A
NCT05466539	PHASE4	COMPLETED	Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A
NCT06250543	PHASE4	COMPLETED	Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder
NCT03960957	PHASE3	COMPLETED	Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT04756882	PHASE2/PHASE3	UNKNOWN	Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars
NCT02221648	PHASE2	TERMINATED	Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain
NCT02907268	PHASE2	COMPLETED	Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study
NCT03978234	PHASE2	UNKNOWN	Evaluating the Safety and Effect of abobotulinumtoxinA in the Gastrocnemius Muscle to Improve Equinus and Plantar Fasciitis Pain
NCT04886167	PHASE1/PHASE2	UNKNOWN	Dysport Dose-Ranging Treatment of Platysmal Bands
NCT05089357	Not specified	COMPLETED	Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
NCT05167864	Not specified	COMPLETED	Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
NCT07452510	Not specified	COMPLETED	Comparison of Dry Needling and Two Botulinum Toxins for Bruxism

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).